Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

ClinicalTrials.gov ID: NCT03611582

Public ClinicalTrials.gov record NCT03611582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. Together with the medicine, the participant will also be part of an intensive lifestyle program where the participant will have talks with study staff about healthy food choices, what the participant can do to lose weight and be more physically active. The participant will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance. The participant will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. For the first 2 months the participant will be on a low calorie diet. The diet is made up of bars, shakes and 1 low calorie pre-prepared meal for each day. The study will last for about 1.5 years. The participant will have 32 clinic visits with the study doctor.

Study identification

NCT ID
NCT03611582
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
611 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 1, 2018 (Actual)
Primary completion
Mar 18, 2020 (Actual)
Completion
Apr 28, 2020 (Actual)
Last update posted
Nov 11, 2021

2018 – 2020

United States locations

U.S. sites
41
U.S. states
17
U.S. cities
39
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35294 —
Novo Nordisk Investigational Site Montgomery Alabama 36106 —
Novo Nordisk Investigational Site Peoria Arizona 85381 —
Novo Nordisk Investigational Site Anaheim California 92801 —
Novo Nordisk Investigational Site Escondido California 92025 —
Novo Nordisk Investigational Site Fresno California 93720 —
Novo Nordisk Investigational Site Fullerton California 92835 —
Novo Nordisk Investigational Site Huntington Beach California 92648 —
Novo Nordisk Investigational Site Los Angeles California 90057 —
Novo Nordisk Investigational Site Walnut Creek California 94598 —
Novo Nordisk Investigational Site Golden Colorado 80401 —
Novo Nordisk Investigational Site Kissimmee Florida 34744 —
Novo Nordisk Investigational Site Panama City Florida 32401 —
Novo Nordisk Investigational Site Plantation Florida 33324 —
Novo Nordisk Investigational Site Roswell Georgia 30076 —
Novo Nordisk Investigational Site Honolulu Hawaii 96814 —
Novo Nordisk Investigational Site Chicago Illinois 60607 —
Novo Nordisk Investigational Site Evanston Illinois 60201-2477 —
Novo Nordisk Investigational Site Skokie Illinois 60077 —
Novo Nordisk Investigational Site Albany New York 12203 —
Novo Nordisk Investigational Site Endwell New York 13760 —
Novo Nordisk Investigational Site Chapel Hill North Carolina 27517 —
Novo Nordisk Investigational Site Greensboro North Carolina 27408 —
Novo Nordisk Investigational Site Hickory North Carolina 28601 —
Novo Nordisk Investigational Site Raleigh North Carolina 27609 —
Novo Nordisk Investigational Site Wilmington North Carolina 28401 —
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104-3317 —
Novo Nordisk Investigational Site Charleston South Carolina 29425 —
Novo Nordisk Investigational Site Mt. Pleasant South Carolina 29464 —
Novo Nordisk Investigational Site Knoxville Tennessee 37912 —
Novo Nordisk Investigational Site Austin Texas 78731 —
Novo Nordisk Investigational Site Dallas Texas 75226 —
Novo Nordisk Investigational Site Dallas Texas 75230 —
Novo Nordisk Investigational Site Dallas Texas 75231 —
Novo Nordisk Investigational Site Rockwall Texas 75032 —
Novo Nordisk Investigational Site Round Rock Texas 78681 —
Novo Nordisk Investigational Site St. George Utah 84790 —
Novo Nordisk Investigational Site Arlington Virginia 22206 —
Novo Nordisk Investigational Site Newport News Virginia 23606 —
Novo Nordisk Investigational Site Winchester Virginia 22601-3834 —
Novo Nordisk Investigational Site Olympia Washington 98502 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03611582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 11, 2021 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03611582 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →